One of the greatest challenges in urological oncology is renal cell carcinoma (RCC), which is the third leading cause of death in genitourinary cancers. RCCs are highly vascularized and respond positively to antiangiogenic therapy. Endostatin (ES) is a fragment of collagen XVIII that possesses antiangiogenic activity. In this study, we examined the potential of ES-based antiangiogenic therapy to activate tumor-associated endothelial cells in metastatic RCC (mRCC). Balb/c-bearing Renca cells were treated with NIH/3T3-LendSN or, as a control, with NIH/3T3-LXSN cells. The T-cell subsets and lymphocyte populations of tumors, mediastinal lymph nodes and the spleen were assessed by flow cytometry. The expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) was assessed by real-time PCR, flow cytometry and immunohistochemistry analysis. ES gene therapy led to an increase in the percentage of infiltrating CD4-interferon (IFN)-g cells (Po0.05), CD8-IFN-g cells (Po0.01) and CD49b-tumor necrosis factor-a cells (Po0.01). In addition, ES therapy caused an increase at the mRNA level of ICAM-1 (1.4-fold; Po0.01) and VCAM-1 (1.5-fold) (control vs treated group; Po0.001). Through flow cytometry, we found a significant increase in the CD34/ICAM-1 cells (8.1-fold; Po0.001) and CD34/VCAM-1 cells (1.6-fold; Po0.05). ES gene therapy induced a significant increase in both T CD4 and CD8 cells in the lymph nodes and the spleen, suggesting that ES therapy may facilitate cell survival or clonal expansion. CD49b cells were also present in increased quantities in all of these organs. In this study, we demonstrate an antitumor inflammatory effect of ES in an mRCC model, and this effect is mediated by an increase in ICAM-1 and VCAM-1 expression in tumor-associated endothelial cells.
INTRODUCTION
Renal cell carcinoma (RCC) is the thirteenth most common cancer worldwide and accounts for 4% of all adult malignancies in the USA.
1 Approximately 25 to 30% of patients with RCC have distant metastases at diagnosis, and another third of RCC patients develop systemic recurrence after primary tumor resection. 2 RCC has several morphological subtypes and the clear cell carcinoma is the most prevalent form (cRCC). cRCC is a highly vascularized tumor. This phenotype is due, in part, to the loss of the von Hippel--Lindau tumor-suppressor gene, as von Hippel--Lindau loss of heterozygosity and/or epigenetic inactivation have been found in 70--90% of clear cell type RCC. 3 Furthermore, RCC cells secrete a variety of proangiogenic cytokines and growth factors that promote angiogenesis and tumor progression. 4, 5 In cases of localized disease, RCC is curable with surgery, but for those patients with distant metastases, the prognosis is poor. 6 The treatment of metastatic renal cell cancer (mRCC) has advanced remarkably as our understanding of the pathogenesis of this disease increases. Recently, several drugs that act on multiple targets, including vascular endothelial growth factor, have shown impressive activities against mRCC with a high percentage of partial response and/or stabilized disease and with a significant impact on survival. 7--10 RCC is frequently infiltrated by cells of the immune system and there are a number of studies regarding their contribution to the antitumor response. 11--13 Up to now, there is no consensus about the prognostic value of tumor-infiltrating lymphocytes (TIL). However, there is an increasing evidence that characterization of TIL sub-populations may provide useful prognostic information. 14 The upregulation of the Th1-type immune response in RCC tumors was correlated with a favorable prognosis. 15 Indeed, type 1 responses have been associated with disease-free status, indicating that the tumor environment may have a role in regulating the polarization of a T-cell response in RCC patients. 16, 17 Endothelial cells constitute a multifunctional cellular system with functions in selective barrier formation and permeability for large and small molecules, hemostasis, vasoregulation and the recruitment of inflammatory immune cells. 18, 19 Tumor-associated endothelial cells can originate by sprouting from locally preexisting vessels or through the recruitment of bone marrow-derived endothelial progenitor cells to provide nutritional support to the growing tumor. Furthermore, these cells serve as an interface between circulating blood cells, tumor cells and the extracellular matrix, thereby having a central role in controlling leukocyte recruitment. 20--22 Leukocyte--vessel wall interactions are mediated by endothelial cell adhesion molecules, such as intercellular adhesion molecule-1 and -2 (ICAM-1 and ICAM-2), vascular cell adhesion molecule-1 (VCAM-1), E-selectin and CD34. 23 Dikxs et al. 24 have demonstrated that angiogenesis inhibitors increase leukocyte--vessel wall interactions in tumor vessels, which lead to increased leukocyte infiltration into tumor tissue. Endogenous inhibitors of angiogenesis are proteins or protein fragments that are formed in the body and can inhibit the formation of blood vessels. Endostatin (ES) is the C-terminal fragment of collagen XVIII generated by proteolytic cleavage by proteases such as cathepsin L, elastase or matrix metalloproteases. 25, 26 ES is a potent endothelial cell-specific inhibitor of angiogenesis. In vitro, ES has been shown to inhibit endothelial cell migration by binding to a5b1 integrin, thereby disrupting cell--matrix adhesion via focal adhesion kinase-mediated extracellular-signal-regulated kinase 1, p38 mitogen-activated protein kinase pathways and the Src-dependent p190RhoGAP pathway. 27 ES also has been shown to induce apoptosis through the Shb adaptor protein and to arrest cell cycle progression by inhibiting cyclin D1. 20 In vivo, ES has been demonstrated to be effective in different tumor models. 28--32 In previous reports from our group, the subcutaneous injection of ES-transduced cells resulted in significant antitumor effects in a murine model of primary and metastatic RCC. 29--32 In the primary RCC model, we have used the immunodeficient mice, which have innate but no adaptive immunity. In this study, besides the reduction of microvascular density and necrosis, the tumors of the treated group also displayed foci of apoptotic cells, which were associated with leukocyte infiltration. 29 In the mRCC model, we used immunocompetent mice. Again, the treated tumors showed a decreased microvascular density as a result of antiangiogenic therapy. In addition, a reduction of the nodule area and a decreased proliferation of tumor cells were found. TILs were also evaluated and the ES-treated group showed a significant increase in CD4 and CD49b populations. 30 In this study, we examined the activation of tumor-associated endothelial cells, the differential distribution of T-cell subsets in metastatic lungs and the recruitment and expansion of CD4, CD8 and CD49b cells in lung, spleen and mediastinal lymph node in tumor-bearing mice after retroviral ES therapy.
MATERIALS AND METHODS

Cell lines
The NIH/3T3-LendSN-clone 3 was utilized for ES expression, and NIH/3T3-LXSN was used as a control, as described in previous work. 29 Both cell lines were maintained in high-glucose-content (4.5 g l --1 at 25 mM) Dulbecco's modified Eagle's medium (DMEM) medium (Life Technologies Corporation, Grand Island, NY, USA) supplemented with 100 U ml --1 penicillin, 100 mg ml --1 streptomycin and 10% fetal bovine serum. The murine kidney carcinoma cell line, Renca (Cell Lines Service, Eppelheim, Germany), was obtained from the murine transplantable renal adenocarcinoma of spontaneous origin. The cells were maintained in RPMI 1640 medium (Life Technologies) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 1% minimal Eagle's medium nonessential amino acids, 100 U ml --1 penicillin and 100 mg ml --1 streptomycin (Gibco-Invitrogen, Carlsbad, CA, USA). All cell lines were maintained in a humid chamber at 37 1C and under 5% carbon dioxide.
Animals
Male Balb/c mice, aged 8--10 weeks, were obtained from the Animal Facility of IPEN/CNEN-SP, São Paulo, Brazil. In these experiments, 30 mice were used (control group ¼ 15, ES-treated group N ¼ 15). All animals were cared for in accordance with the standards of the institute under a protocol approved by the Animal Experimentation Ethics Committee (number of process: 87/11).
Orthotopic RCC tumor model
Mice were anesthetized by intraperitoneal injection with ketamine (100 mg kg --1 body weight, Ketalar; Parke-Davis, Morris Plains, NJ) and xylazine (10 mg kg --1 body weight, Phoenix Scientific, St Joseph, MO). The left flank region underwent trichotomy and incision. The left kidney was exposed, and 2 Â 10 5 Renca cells suspended in 10 ml phosphate-buffered saline (PBS) with the aid of the glass syringe (Hamilton, Reno, NV, USA) were inoculated into the renal subcapsular space. The kidney was subsequently returned, and the muscles and skin were sutured using surgical clips.
The left kidney was removed by unilateral nephrectomy 7 days after Renca cell inoculation. The mice were divided into two experimental groups: the control group and the ES-treated group. Both groups received a subcutaneous injection of 3.6 Â 10 6 NIH/3T3-LXSN and NIH/3T3-LendSNclone 3 (ES production levels ¼ 1.35 mg ml --1 ), respectively.
Plasma ES levels determination
At the end of the experiment, the blood samples of mice were taken into test tubes with EDTA, plasma components separated and then frozen at À20 1C. Samples were thawed at the time of study and plasma ES levels were measured using a murine ES enzyme immunoassay kit (USCN Life Science and Technology Company, Wuhan, China), in accordance with the manufacturer's instructions. The ES concentrations were determined at least in duplicate, and the assay reproducibility was confirmed. ELISA plates were read using the Microplatelets MR 4000 Reader (Dynatech, Boston, MA, USA).
Flow cytometry analysis
Isolation of tumor-associated endothelial cells. Whole lungs were perfused with 20 ml cold PBS and maintained in RPMI 1640 medium. Endothelial cells were isolated as previously described with minor modifications. 33 The tissue was minced using surgical scissors and treated with an enzymatic solution of collagenase D (1 mg ml --1 ) (Roche, Mannheim, Germany) and 2.5 U ml À1 of dispase type II (Boehringer Mannheim, Mannheim, Germany). The tissue suspension was incubated for 30 min at 37 1C in a water bath with continuous agitation. After this treatment, the enzymatic solution was inactivated by adding RPMI 1640 medium with 10% fetal bovine serum and was immediately centrifuged at 400 g for 5 min at 4 1C. The cell suspension was filtered through a 70-mm cell strainer and was centrifuged, as described above. Next, the cells were resuspended in RPMI 1640 and carefully placed onto Ficoll-paque PLUS (GE Healthcare, Uppsala, Sweden) in a 15-ml tube. The cell suspension was centrifuged at 400 g for 20 min at 18 1C without braking. The cells were collected from their respective density fractions and prepared for flow cytometry analysis.
Approximately 5 Isolation of immune cells. The perfused lungs were minced with scissors and dissociated in collagenase D (Roche) at 2.5 mg ml --1 for 45 min at 37 1C. Next, DMEM medium with 10% fetal bovine serum was added and centrifuged at 450 g for 5 min at 4 1C. The tissue suspension was passed through a 70-mm cell strainer, subjected to discontinuous Percoll gradient separation (GE Healthcare) using the dilutions 37 and 70% and centrifuged at 950 g for 20 min with the brakes off. The cells collected from the respective density fractions were directly prepared for flow cytometry analysis.
The spleens were macerated, suspended in DMEM medium and centrifuged at 450 g for 5 min at 4 1C. Red blood cells were lysed with ACK buffer (Sigma; St Louis, MO). The cell suspension was filtered through a 70-mm cell strainer, washed in PBS and subsequently centrifuged at 450 g for 5 min at 4 1C, suspended in DMEM medium and used as described.
The mediastinal lymph nodes were macerated, suspended in DMEM medium and centrifuged at 450 g for 5 min at 4 1C. The supernatant was discarded, and the cells were resuspended in DMEM medium. 
Histological and immunohistochemistry analysis
Metastatic lungs were excised, washed in PBS, fixed in Methacarn (60% methanol, 30% chloroform and 10% glacial acetic acid) for 3 h and routinely processed for paraffin embedding. Histological analysis was performed in 4 mm sections stained with hematoxylin and eosin.
Lung metastatic foci were quantified by microscopic inspection of hematoxylin and eosin-stained lung sections. Hematoxylin and eosin (H&E) stained sections (N ¼ 6 animals per group, 10 sections per lung) were analyzed under a light microscopy and the number of metastatic foci were counted. The quantification was performed at a Â 5 magnification using microscopy Leica DM1000 (Leica Microsystems, Wetzlar, Germany).
For immunohistochemistry analysis tissue sections were cut, hydrated and incubated with 85% formic acid for 3 min. The sections were subjected to antigen retrieval with citrate buffer 10 mM, pH 6.0, in a pressure cooker for 1 min at 125 1C and 25 psi. The slides were blocked with hydrogen peroxide (10 V) and methanol for 5 min. The preparations were blocked for 30 min in a solution containing 6% milk in PBS. Next, the slides were incubated with monoclonal anti-VCAM-1 (H-276, Santa Cruz, 1:50) and monoclonal anti-ICAM-1 (5K16, Santa Cruz, 1:50) overnight in a humidified chamber at 4 1C. After several PBS washes, the slides were incubated with the reagents supplied by the manufacturers of Novolink Polymer Detection Systems (RE7150-K, Leica Microsystems, Bannockburn, IL) and the diaminobenzine visualization system. All of the procedures and incubation times followed the specification of the manufacturer's data sheets. The slides were counterstained with hematoxylin, dehydrated in ethanol, cleared in xylene and mounted using Erv-rmount (EasyPath, Erviegas, São Paulo, SP, Brazil). The images were obtained using an microscope (Leica DM1000), a digital compact camera (Leica DFC420C) and an image processor (Leica Application Suite v3.3.0).
RNA extraction
Metastatic lung tissue (100 mg) was homogenized on a rotor-stator Precellys 24 (Bertin Technologies, Montighy-le-Bretonneux, France) in 1 ml of Qiazol lysis Reagent (Qiagen, Germantown, MD, USA) in a CK28 beads tube (Bertin Technologies). After the addition of 200 ml of chloroform (Merck, Darmstad, Germany), samples were vortexed and left for 15 min before phases were separated by centrifugation at 12 000 g for 15 min at 4 1C (Centrifuge 5415 R, Eppendorf AG, Hamburg, Germany). The aqueous phase (RNA) was precipitated with 500 ml of isopropanol and centrifuged at 12 000 g for 10 min at 4 1C. The resulting pellet was resuspended in 1 ml of 75% ethanol, vortexed and centrifuged at 10 500 g for 5 min at 4 1C. Next, the pellet was dissolved in 50 ml of diethylpyrocarbonate (DEPC)-treated H 2 O (Invitrogen). Total RNA quantification was performed on a Nanodrop spectrophotometer (ND-100, Thermo Fisher Scientific Inc., Waltham, MA, USA), after which samples were stored at À80 1C until analysis.
Reverse transcription-polymerase chain reaction (RT-PCR)
For the total RNA analysis, RNA samples from above were was treated with RNase-Free DNase (Promega, Heidelberg, Germany) according to the manufacturer's instructions. The complementary DNAs were synthesized from 4 mg of total RNA added to 2 mg of OligodT (Invitrogen), 8 ml FS buffer 5 Â (Invitrogen), 2 ml dNTP (10 mM), 2 ml dithiothreitol (0.1 M, Invitrogen), 2 ml RNAseOUT (40 U ml --1 , Invitrogen) and 2 ml Moloney Murine Leukemia Reverse Transcriptase (M-MLVRT) (200 U ml Real-time PCR was performed using the TAQMAN system for VCAM-1, ICAM-1 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) genes. The following primers used to VCAM-1, ICAM-1 and an internal control GAPDH mRNA were obtained from Applied Biosystems (Foster City, CA, USA): VCAM-1 (Mm01320973), ICAM-1 (Mm00516023_m1) and GAPDH (Mm99999915_g1). Amplification was carried out by real-time PCR (7300 System, Applied Biosystems) as follows: 50 1C for 2 min, 95 1C for 10 min, and 40 cycles of 95 1C for 15 s and 60 1C for 1 min.
The statistical analysis of the quantitative RT-PCR results was performed using the DCt value (Ct gene of interest ÀCt GAPDH ). Relative gene expression was obtained by DDCt methods (DCt sample ÀDCt GAPDH ) using the control group as a reference for comparison of every unknown sample gene expression level. The conversion formula between DDCt and relative gene expression levels used is fold change ¼ 2
ÀDDCt
.
Statistical analysis
The results are presented as the mean ± s.e. Single comparisons of the mean values were performed by Student's t-test. Multiple comparisons were performed using one-way analysis of variance followed by Bonferroni's test, using GraphPad Prism, version 4.0 (GraphPad Software, San Diego, CA). Po0.05 was considered statistically significant.
RESULTS
In our previous studies, 29, 32 we demonstrated that primary and metastatic renal tumors treated with ES displayed significant regression. In addition to the already characterized biological activities of ES, including the reduction of vascularization, we also noted a dense infiltration of leukocytes present in all ES-treated tumors. In this study, our aim was to determine if ES could cause tumor-associated endothelial cell activation and interfere with the homing of lymphocytes to mRCC.
Balb/c mice were orthotopically injected with murine Renca cells. At the end of the experiment, ES plasma levels of normal and experimental groups were measured. The presence of metastases Figure 1 . Endostatin (ES) plasma levels were measured in the normal, control and ES-treated groups. The presence of metastases led to a significant increase in the plasma ES levels (normal vs control group; *Po0.05). However, the ES-treated group showed even higher ES plasma levels (normal vs ES-treated group, ***Po0.001; control group vs ES-treated group, **Po0.01; analysis of variance (ANOVA) test).
led to a 1.61-fold increase in the plasma ES levels (normal vs control group; Po0.05) (Figure 1) . Moreover, subcutaneous inoculation of NIH/3T3-LendSN cells resulted in a 2.40-fold increase in the ES circulating levels in ES-treated group (normal vs ES-treated group; Po0.001). Also, there was a significant difference between ES circulating levels of control and ES-treated group (control group vs ES-treated group; Po0.01) (Figure 1 ).
The number of the metastatic foci was significantly reduced in lung of ES-treated mice Lung tissue sections were counted for number of metastatic foci (Figures 2a and b) . The number of metastatic foci in the lung parenchyma of ES-treated group was (12.8 ± 1.6), which was significantly lower than that of control group (63.4±9.2; Po0.001) (Figure 2c ).
CD4-IFN-g cells, CD8-IFN-g cells and CD49b-TNF-a cells were significantly increased in lung nodules of ES-treated mice
To assess the effector function of T cells from the lungs, the cells were cultured for 20 min in the presence of anti-CD4, anti-CD8 and CD49b antibodies and assayed for IFN-g or TNF-a production by intracellular flow cytometry. The percentages of CD4-IFN-g, CD8-IFN-g and CD49b-TNF-a cells of the total cells obtained from tissues homogenates were determined by flow cytometry (Figure 3a) .
In the lungs, ES therapy significantly enhanced the effector responses of the three populations. The CD4-IFN-g cell percentage increased 1.8-fold (Po0.05 vs control), whereas CD8-IFN-g cells increased 1.9-fold (Po0.01 vs control), and a marked increase in 2.7-fold was observed for the CD49b-TNF-a cells, (Po0.001 vs control) (Figures 3b--d) .
Upregulation of VCAM-1 and ICAM-1 mRNAs by ES gene therapy
The expression of ICAM-1 and VCAM-1 was assessed by RT-PCR and flow cytometry. Both techniques confirmed a significant upregulation of these adhesion molecules in response to ES gene therapy. By RT-PCR, the ICAM-1 expression level increased 1.4-fold (control vs treated group; Po0.01), and VCAM-1 expression increased 1.5-fold (control vs treated group; Po0.001) (Figure 4a ).
To analyze tumor-associated endothelial cells activation by flow cytometry, ECs were freshly isolated from metastatic lungs and double-stained for CD34/ICAM-1 and CD34/VCAM-1. In the control group, the percentage CD34/VCAM-1 cells was significantly higher than that of CD34-ICAM-1 cells (Po0.01) (Figure 4c ). However, in the ES-treated group, the upregulation of CD34-ICAM-1 was more pronounced (8.1-fold; control vs treated group; Po0.001) (Figure 4e ) than the upregulation of CD34-VCAM-1 (1.6-fold; control vs treated group; Po0.05) (Figure 4d) .
The flow cytometry findings were corroborated by immunohistochemistry findings (Figure 4b ).
Recruitment and expansion of CD4, CD8 and CD49b cells in lung, spleen and mediastinal lymph node in tumor-bearing mice The phenotypes of the T cells within the lungs, spleen and mediastinal lymph nodes were determined by flow cytometry. Single-cell homogenates were prepared and analyzed for CD4-, CD8-or CD49b-positive cells. The percentage of each T-cell subpopulation was quantified and used to calculate the total T-cell number present in each organ.
In the lungs, as well in the secondary lymphoid tissues, both adaptive and innate immune responses were activated by ES therapy. The increase in CD4-T cells was 1.6-fold (Po0.01 vs control) in the lungs, 1.3-fold in the spleen (Po0.01 vs control) and 1.2-fold in the lymph nodes (Po0.01 vs control) (Figure 5b and Table 1 ).
For CD8-T cells, the ES treatment led an increase in the cytotoxic T-cell count of 1.2-fold in the lungs (Po0.05 vs control), 1.1-fold in the spleen (Po0.05 vs control) and 1.2-fold in the lymph nodes (Po0.01 vs control) (Figure 5c and Table 1 ). Of the immune subset of T cells, CD49b cells were the most significantly increased in all organs. The lungs were the most common location for CD49b cells after ES therapy, showing an increase in 3-fold (Po0.01 vs control) followed by the spleen with a 2-fold increase (Po0.001 vs control) and the lymph nodes with a 1.8-fold increase (Po0.01 vs control) (Figure 5d and Table 1 ).
DISCUSSION
Tumor microenvironment is a complex niche that encompasses, besides the supportive matrix and soluble factors, a multiple cell types, such as stromal cells, vascular cells and cells of the immune system. The type, density and location of immune cells in the tumor can affect the prognosis of patients. 34 Accordingly, we previously demonstrated that in addition to its antiangiogenic activities, ES treatment elicits a potent proinflammatory and antitumor response. 29 In this study, we examined changes in the tumor microenvironment after ES therapy, examining populations of TILs and their homing to secondary lymphoid organs and tumors.
Mice bearing mRCC showed the endogenous ES plasma levels significantly higher than the control group. This phenomenon has been demonstrated in patients with advanced stages of clear RCC and could be explained by the action of matrix metalloproteases. In these patients, the proteolytic activity of matrix metalloprotease-9 was elevated. 35 In the ES-treated group, the circulating ES levels were 1.52-fold higher than the control group and, corroborating our previous data, 31 these levels caused a reduction of metastatic foci number.
Tumor escape from immune surveillance is partly due to the downregulation of endothelial adhesion molecules that are necessary for leukocyte--vessel wall interactions. 17, 36, 37 Pro-inflammatory stimuli, such as TNF-a, interleukin-1 and IFN-g, have an important role in the upregulation of integrins, selectins and chemokines. By flow cytometry, we found an increased percentage of the CD4-IFN-g, CD8-IFN-g and CD49b-TNF-a cells in the metastatic lung TIL of ES-treated mice. Besides the recognized antitumoral action, this phenotype can be correlated with the induction of ICAM-1 and VCAM-1 in tumor-associated endothelial cells. Moreover, our RT-PCR analysis confirmed the upregulation of These findings strongly suggested that ES therapy generates an inflammatory microenvironment through a circumvention of EC anergy. In the RCC model, it has already been established that ICAM-1 is important for TIL--RCC interactions, including TILmediated cytotoxicity and TIL proliferation. 38 Additionally, the upregulation of VCAM-1 and its prognostic significance have been reported in several human malignances, including RCC, where it was associated with improved survival for patients with advanced mRCC. 39 Following these observations, we analyzed the differential distribution of T-cell subsets in the spleen, mediastinal lymph nodes and the metastatic lung. Interestingly, ES gene therapy induced a significant increase in both T CD4 and CD8 cells in the lymph nodes and spleen, suggesting that ES may facilitate cell survival or clonal expansion. This result was associated with an increased frequency of both CD4 and CD8 TILs in the lungs. Moreover, CD49b cells were also present in larger quantities in all of these organs. It is noteworthy that this finding is corroborated by previous findings that were obtained by our lab and that employed a bicistronic vector expressing ES þ interleukin-2. 32 In this context, ES has an important role in the amplification of the immune response in the lymph nodes, thereby leading to a more activated phenotype of effector cells. It is noteworthy that cellular adhesion-associated molecules were also upregulated. This result led to a more intense tumor inflammatory infiltration.
The ES signaling pathway depends on its receptor expression and the sharing of its signaling subunit, gp30. 40 Interleukin-6 is considered to be an important inflammatory cytokine, specifically in autoimmune diseases, such as experimental autoimmune encephalomyelitis and rheumatoid arthritis. 41, 42 This property may indicate the molecular pathway used by ES to upregulate the molecules observed in this study. Indeed, whether ES has an important role in the commitment of both Th and Th7 cells is a topic of future interest in our lab.
Taken together, our data indicate that in mRCC, the antitumor inflammatory effects of ES might be due to tumor-associated endothelial cell activation, thereby highlighting the use of ES as a promising possible therapeutic tool. Statistical significance for a specific immune compartment between control and ES-treated groups was designated as *Po0.05, **Po0.01 and ***Po0.001.
